InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $14.210 0.14 (1%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$4,828 AGM Notice of Meeting and Proxy Form 18 Apr 2019 8:38AM $0.950 $14.210 risen by 1,395.79%
$4,828 Non-Deal Roadshow Presentation March-April 2019 26 Mar 2019 11:40AM $0.705 $14.210 risen by 1,915.60%
$4,828 Telix and Cyclotek Manufacture VisAct ImmunoPET Tracer 21 Mar 2019 8:33AM $0.655 $14.210 risen by 2,069.47%
$4,828 cGMP Manufacturing of TLX250 Renal Cancer Therapy Complete 20 Mar 2019 8:27AM $0.680 $14.210 risen by 1,989.71%
$4,828 EAU issues updated prostate cancer imaging guidelines 18 Mar 2019 8:28AM $0.685 $14.210 risen by 1,974.45%
$4,828 ANMI Acquisition - Voluntary Escrow Shares to be released 6 Mar 2019 1:01PM $0.690 $14.210 risen by 1,959.42%
$4,828 Annual Report 2018 28 Feb 2019 3:58PM $0.715 $14.210 risen by 1,887.41%
$4,828 Appendix 4E - Summary of Results 28 Feb 2019 3:56PM $0.715 $14.210 risen by 1,887.41%
$4,828 Corporate Governance Statement 28 Feb 2019 3:52PM $0.715 $14.210 risen by 1,887.41%
$4,828 Appendix 4G - Key to Governance Disclosures 28 Feb 2019 3:52PM $0.715 $14.210 risen by 1,887.41%
$4,828 Telix appoints Gabriel Liberatore as Group COO 18 Feb 2019 2:50PM $0.700 $14.210 risen by 1,930%
$4,828 Appendix 4C - December 2018 quarter 31 Jan 2019 8:19AM $0.755 $14.210 risen by 1,782.12%
$4,828 Appendix 3B - issue of unlisted share options 24 Jan 2019 1:48PM $0.750 $14.210 risen by 1,794.67%
$4,828 Telix Group Expands Prostate Imaging Capability through ININ 24 Jan 2019 9:49AM $0.755 $14.210 risen by 1,782.12%
$4,828 Detailed Program Update - January 2019 9 Jan 2019 8:21AM $0.720 $14.210 risen by 1,873.61%
$4,828 Investor Presentation and Program Update 8 Jan 2019 8:43AM $0.655 $14.210 risen by 2,069.47%
$4,828 Update - Acceleration of Prostate Cancer Therapy Program 8 Jan 2019 8:29AM $0.655 $14.210 risen by 2,069.47%
$4,828 Appendix 3B - Issue of Consideration Shares 24 Dec 2018 8:23AM $0.650 $14.210 risen by 2,086.15%
$4,828 Cleansing Notice - Issue of Consideration Shares 24 Dec 2018 8:23AM $0.650 $14.210 risen by 2,086.15%
$4,828 Telix Pharmaceuticals Completes Acquisition of ANMI SA 24 Dec 2018 8:23AM $0.650 $14.210 risen by 2,086.15%
$4,828 Appointment of Nannette Rich to Lead US Sales & Marketing 21 Dec 2018 8:27AM $0.615 $14.210 risen by 2,210.57%
$4,828 Renal Cancer Imaging Program - Japanese Regulatory Update 19 Dec 2018 8:26AM $0.590 $14.210 risen by 2,308.47%
$4,828 TLX250 ZIR-DOSE Clinical Study Completes Enrolment 19 Dec 2018 8:26AM $0.590 $14.210 risen by 2,308.47%
$4,828 ANMI Investor Conference Call - link to audio recording 3 Dec 2018 8:26AM $0.675 $14.210 risen by 2,005.19%
$4,828 Nihon Medi-Physics Collaboration on Actinium Renal Cancer 29 Nov 2018 8:29AM $0.690 $14.210 risen by 1,959.42%

826 - 850 of 948 results

Page 34 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.